Carlton:
NMPS is burning at $8.5 million/year with $12 million in-hand. I owned them when they were ripping up a couple of years ago, but the penetration of the bladder product is even slower than the snail's pace that I predicted upon bailing. If Bayer doesn't elect to develop a cervical test, then it's pushing up daisies, IMO. On the other hand, many bios have hit tax-selling woes big-time, and today's action in NMPS looks like it's just getting creamed.
Several really good biotechs are suffering the same fate.... dump at any cost. I usually cherry-pick low-cost issues at this time of year, but I'm also dumping losers to try to offset some good gains. I ask myself...... "if you're doing this, imagine the mind set of the non-biotech freak". I'd look for bounce potential in selected, quality issues..... ARIA for example. Sentiment is so negative that, if there's justice, an ARIA should outperform a NMPS.
Check out today's ARQL activity. Every now and then I feel as though the selling overhang may be gone. Haven't been correct yet.
Ray.... would love it if you could keep an eye on MDYN.
To all...... boy, did I pick the wrong start for "biotech season". I've gotten hammered. GLIA worked out as expected, but geze, DEPO! Would love to say "iab", but my last "iab" was a no-go, and I'm probably a couple of weeks removed. I shall return. In the interim, I see that Mr. Market Cap (John) is doing great.
Cheers! Rick |
